Female and male participants aged 18 to 80 years (inclusive) at the time of informed consent,
Diagnosis of ulcerative colitis (UC) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report,
Inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason,
Female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms,
You may not be if
Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or Crohn's disease (CD),
Findings suggestive of CD (e.g. fistulae, granulomas on biopsy),
Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed,
Gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture,
Evidence of fulminant colitis or toxic megacolon at screening,
Current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine,
Previous surgery or anticipated surgical intervention for UC (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor),
Any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery,
Clareo Health | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
